• +1-646-491-9876
    • +91-20-67278686

    Search

    Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2017

    Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2017

    • Report Code ID: RW0001709435
    • Category Pharmaceuticals
    • No. of Pages 50
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2017, provides an overview of the Female Hypoactive Sexual Desire Disorder (Women's Health) pipeline landscape.

    Hypoactive sexual desire disorder (HSDD) is an absence of sexual fantasies and desire for sexual activity. The predisposing factors include anxiety, depression, androgen deficiencies, and chronic debilitating illnesses, such as chronic renal failure, hyper-prolactinaemia and hypo-hyperthyroid states. Treatment includes antidepressant and hormone therapy.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Female Hypoactive Sexual Desire Disorder (Women's Health) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Female Hypoactive Sexual Desire Disorder (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Hypoactive Sexual Desire Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Unknown stages are 2, 4 and 1 respectively.

    Female Hypoactive Sexual Desire Disorder (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Female Hypoactive Sexual Desire Disorder (Women's Health) .
    - The pipeline guide reviews pipeline therapeutics for Female Hypoactive Sexual Desire Disorder (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Female Hypoactive Sexual Desire Disorder (Women's Health) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Female Hypoactive Sexual Desire Disorder (Women's Health) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Female Hypoactive Sexual Desire Disorder (Women's Health)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Female Hypoactive Sexual Desire Disorder (Women's Health) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Female Hypoactive Sexual Desire Disorder (Women's Health) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Female Hypoactive Sexual Desire Disorder - Overview
    Female Hypoactive Sexual Desire Disorder - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Female Hypoactive Sexual Desire Disorder - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Female Hypoactive Sexual Desire Disorder - Companies Involved in Therapeutics Development
    Apricus Biosciences Inc
    Emotional Brain BV
    GlaxoSmithKline Plc
    Palatin Technologies Inc
    Valeant Pharmaceuticals International Inc
    Female Hypoactive Sexual Desire Disorder - Drug Profiles
    (sildenafil citrate + testosterone) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    alprostadil - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BP-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    bremelanotide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    gepirone hydrochloride ER - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SIP-104 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SPT-201 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Female Hypoactive Sexual Desire Disorder - Dormant Projects
    Female Hypoactive Sexual Desire Disorder - Product Development Milestones
    Featured News & Press Releases
    Mar 20, 2017: Palatin Technologies Receives Notice of Allowance on Bremelanotide Methods of Use Patent for Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women
    Feb 27, 2017: AMAG and Palatin Announce Rekynda Data Presentations at the International Society for the Study of Women's Sexual Health Annual Meeting
    Nov 01, 2016: Bremelanotide Meets Co-Primary Endpoints in Palatins Phase 3 Trials for Hypoactive Sexual Desire Disorder
    Sep 23, 2016: Palatin Technologies Presents Bremelanotide Neurobiology and Treatment Efficacy Review at World Meeting on Sexual Medicine
    Aug 04, 2016: Palatin Technologies Announces Completion of All Patient Visits In Phase 3 Clinical Trials of Bremelanotide for Hypoactive Sexual Desire Disorder
    Nov 02, 2015: Nicolas Sitchon, CEO of S1 Biopharma, to Present at BIO-Europe 2015 Conference
    Aug 20, 2015: S1 Biopharma Supports FDA Approval of First-Ever Treatment for Hypoactive Sexual Desire Disorder
    Jul 29, 2013: S1 Biopharma Doses First Patients in Phase 2a Clinical Trial of Lorexys in Premenopausal Women with HSDD
    Feb 20, 2012: S1 Pharma Submits IND Application For SIP-104 For Treatment Of Hypoactive Sexual Desire Disorder
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Female Hypoactive Sexual Desire Disorder, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Female Hypoactive Sexual Desire Disorder - Pipeline by Apricus Biosciences Inc, H1 2017
    Female Hypoactive Sexual Desire Disorder - Pipeline by Emotional Brain BV, H1 2017
    Female Hypoactive Sexual Desire Disorder - Pipeline by GlaxoSmithKline Plc, H1 2017
    Female Hypoactive Sexual Desire Disorder - Pipeline by Palatin Technologies Inc, H1 2017
    Female Hypoactive Sexual Desire Disorder - Pipeline by Valeant Pharmaceuticals International Inc, H1 2017
    Female Hypoactive Sexual Desire Disorder - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Female Hypoactive Sexual Desire Disorder, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Apricus Biosciences Inc
    Emotional Brain BV
    GlaxoSmithKline Plc
    Palatin Technologies Inc
    Valeant Pharmaceuticals International Inc

    Request for Sample

    Report Url http://www.reportsweb.com//female-hypoactive-sexual-desire-disorder-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//female-hypoactive-sexual-desire-disorder-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//female-hypoactive-sexual-desire-disorder-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments